ACB ACB
Company Profile ↓Company Overview
ACB (ACB) is a publicly traded company listed on with a market capitalization of $171.54M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Revenue has grown at a 13.1% CAGR over the past five years.
Recent Developments
- Mar 2026 Revenue of $320.59M (+11.0% YoY); net profit $-135.96M.
- Trailing 12 Months Year-on-year growth — revenue +11.0%.
- 5-Year Trend Long-term compounding — revenue CAGR 13.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 13.14% |
| 1 Year: | 10.97% |
Stock Price Performance
| 1 Year: | -37.01% |
| 6 Months: | -28.33% |
| 3 Months: | -15.41% |
| 1 Month: | +8.99% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)58.96 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 13.1% over 5 years.
CONS
- Trading 53.3% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 90.54M | 98.02M | 90.37M | 94.19M | 38.01M |
| Cost of Revenue | - | 68.64M | 70.07M | 58.08M | 47.57M | 8.22M |
| Gross Profit | - | 21.90M | 27.95M | 32.29M | 46.62M | 29.79M |
| Operating Expenses | - | 50.15M | 48.17M | 50.56M | 44.44M | 39.82M |
| Operating Income | - | -28.25M | -20.22M | -18.27M | 2.18M | -10.03M |
| EBITDA | - | -11.43M | -11.43M | -38.52M | 6.92M | 3.70M |
| Interest Expense | - | 2.61M | 1.77M | 2.22M | 2.11M | -4.29M |
| Pretax Income | - | -19.99M | -19.38M | -46.98M | -1.58M | 11.41M |
| Tax Provision | - | 1.99M | -3.00K | 6.19M | 164.00K | -4.26M |
| Net Income | - | -24.56M | -15.21M | -51.47M | 1.82M | -71.10M |
| Diluted EPS | 0.51 | - | -0.27 | -0.91 | 0.03 | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Jun 2022 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Revenue | 221.34M | 269.64M | 288.91M | 320.59M |
| Cost of Revenue | 200.11M | 137.91M | 107.96M | 183.94M |
| Gross Profit | 21.23M | 131.73M | 180.95M | 136.65M |
| Operating Expenses | 240.60M | 162.78M | 170.52M | 183.31M |
| Operating Income | -219.38M | -31.05M | 10.43M | -46.66M |
| EBITDA | -1.55B | -11.06M | 46.41M | -40.52M |
| Interest Expense | 71.81M | 13.80M | 2.52M | 1.81M |
| Pretax Income | -1.72B | -57.64M | 31.30M | -56.52M |
| Tax Provision | -2.14M | -554.00K | 4.25M | 2.10M |
| Net Income | -1.72B | -69.33M | 1.59M | -135.96M |
| Diluted EPS | -79.90 | -1.52 | 0.04 | -2.14 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Jun 2022 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Total Assets | 1.08B | 838.67M | 852.67M | 601.09M |
| Current Assets | 745.12M | 426.61M | 478.33M | 397.45M |
| Cash & Equivalents | 437.81M | 136.09M | 137.92M | 64.69M |
| Inventory | 139.93M | 186.38M | 239.09M | 175.07M |
| Receivables | 28.66M | 40.54M | 35.02M | 41.97M |
| Total Liabilities | 422.00M | 236.80M | 244.07M | 89.25M |
| Current Liabilities | 130.86M | 124.62M | 110.86M | 66.93M |
| Long Term Debt | 199.65M | 4.90M | 40.19M | - |
| Total Debt | 269.49M | 104.79M | 104.58M | 23.86M |
| Total Equity | 661.84M | 559.77M | 567.17M | 511.83M |
| Shares Outstanding | 29.78M | 54.55M | 56.23M | 58.95M |
Cash Flows (Annual)
Figures in USD.
| Metric | Jun 2022 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Operating Cash Flow | -110.27M | -68.51M | 16.01M | -13.51M |
| Investing Cash Flow | -36.17M | -3.36M | -14.33M | -72.61M |
| Financing Cash Flow | 147.78M | -47.92M | -116.00K | 9.76M |
| Capital Expenditure | -32.21M | -16.83M | -15.05M | -22.55M |
| Free Cash Flow | -142.48M | -85.34M | 952.00K | -36.06M |
| Net Change in Cash | 1.34M | -119.79M | 1.56M | -76.36M |
Ratios (Annual)
Figures in %.
| Metric | Jun 2022 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Gross Margin % | 9.6% | 48.9% | 62.6% | 42.6% |
| Operating Margin % | -99.1% | -11.5% | 3.6% | -14.6% |
| Net Margin % | -776.0% | -25.7% | 0.6% | -42.4% |
| ROE % | -259.5% | -12.4% | 0.3% | -26.6% |
| ROCE % | -23.0% | -4.3% | 1.4% | -8.7% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ACB
Aurora's 59,000-square-foot facility gains 3-year EU-GMP certification - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxPbjAxMF9mUkJmNWRmRmJYT3YxTGF4MHYwd3E3eTJHaGpwd3lvOWFnWXNiTlh2V21vdGpJSnFZWGVxZ2doZHFpUFBGbnJfSktHV3Z2c2VPUEdpNzhNUTJLOGE2d0gtR1BGNTd1bDVKUU51QWpUQjhPaUh6bnNUekZYLUNGeVZDdFlaSk1mcn…
Aurora Cannabis Inc. (ACB) Q1 Earnings and Revenues Beat Estimates - Yahoo! Finance Canada
<a href="https://news.google.com/rss/articles/CBMigAFBVV95cUxNZ1dhZWw4aTdVY002V0JWSnNBX2NSVXFUNWtkcFhlblpUei1DQjVLeGFVMDhpcmNkSlFzTVAyVzRLeU1PR0FvOXdvM0xjUWI5eUEzWjlWOGRzb05TR29nOXFvU25SOE83NjVrSVFsRXdMYUJlelFrZ2w0aTU1bDdMYQ?oc=5" target="_…
Aurora Cannabis stock gains after Q1 results (ACB:NASDAQ) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMikAFBVV95cUxQb2g4ckN6amp0amxyeGt0Rzdvak1VSmxCd3Y2WklmQzFSblI5VlpWOGppX1N1Y0MwM0dxWkx2dm9wZkVQa1dicS13Wm5hdEpzMkJadWZubDFpTThaRjdIRDd6SjNMaHh0cHhhRUlWUl9RMWZZX3Rtbnl1eDBhZktla1YzemstMUE4ZFNjZG…
TLRY Vs CGC Vs ACB: Which Cannabis Stock Gets The Biggest High If Regulatory Fog Clears? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxOd0NXWWdQblRjOHJ5Y0FXb0MwaFcwdW1tVE9SMmVOb1A5YV9nM0x3dHM5UDZiaTB5RTFoOG9wb2VDVFVCRG8yNXJhVG10VlV4VmxHa0huaTQ4SEVvX2RjeXBUNFFmQWNpMmc5OHZnVFRXRVhzWm5YSXJ2anVaSlF0dGppVExLakdXX0NPZG…
Aurora Cannabis Inc. stock rises Monday, still underperforms market - MarketWatch
<a href="https://news.google.com/rss/articles/CBMi2wFBVV95cUxPTVJmdDhkYnRIeHJqdFViSEdMSS1jMmp0MUtTeDdEQ0FhbjJoQjlkbFd0WUtIM1NaVEpSTjI5TTJpSXBwU2syanlabEhPbEg2OTg4d296UEVkRWJQaW9GWUg1aC05VktrUEFFZ0pyWkVaN3YyZG5DdjVPQTdNRUNHUE9VV0Y5TVNTYXFpUj…
ACB Stock Down 28% in Three Months: Time to Buy the Dip or Cash Out? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxNdnd1YVdzT0RhZVhQdlBxQURTQWJEcEZxTmJHR3AxemtwY0FNMXI1SWVhT1MzQ3FPNERaRVZnZDhYbWd6ZzNObHR4VzlXUURYYWdVTktZZHFxYk9fckRGZWhFMHpmUURvWkVTcUc3RUoyYkxsd1JjanpLczlmMkZIMUpWcUNnQVJQbWl1Mm…
ACB — Frequently Asked Questions
What is the current share price of ACB?
As of 2026-08-05 17:25 PDT, ACB trades at $2.91 on NASDAQ/NYSE. Its 52-week range is $2.58 to $6.23.
What is the market capitalisation of ACB?
ACB has a market capitalisation of $171.54M on NASDAQ/NYSE.
What is the P/E ratio of ACB?
ACB trades at a trailing price-to-earnings (P/E) ratio of -1.36. Its price-to-book (P/B) ratio is 0.34.
What is the return on equity (ROE) of ACB?
ACB has a return on equity (ROE) of -26.56%. Its return on capital employed (ROCE) is -8.74%.
Is ACB a good stock to buy?
This page provides a data-driven analysis of ACB, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.